Vincent L. Cryns, MD Print Friendly Page
Dr. Cryns is Chief of the Division of Endocrinology, Diabetes and Metabolism. His major clinical interests are osteoporosis, general endocrinology and metabolic disorders.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
Endocrinology, Diabetes & Metabolism
Massachusetts General Hospital, Boston, MA, MA
Dartmouth Hitchcock Medical Center, Lebanon, NH
Massachusetts General Hospital, Boston, MA, MA
Harvard Medical School, Boston, MA, 1987
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Dr. Cryns' research focuses on understanding how cells die. He leads a team of scientists who are interested in understanding how abnormalities in cell death contribute to cancer and obesity and in translating these insights into improved therapies. Dr. Cryns' research is funded by the NIH, the Breast Cancer Research Foundation, and other agencies. His work has been featured on National Public Radio's "All Things Considered" and highlighted in Nature and Nature Reviews Cancer. Dr. Cryns has been the recipient of several awards, including an Outstanding Junior Faculty Award from the Avon Foundation, and he is an elected member of the American Society for Clinical Investigation.
Malin D Strekalova E Petrovic V Rajanala H Sharma B Ugolkov A Gradishar WJ Cryns VL .
ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo. Oncogene. 2015 Nov 5;34(45):5626-34
[PubMed ID: 25684139]
Strekalova E Malin D Good DM Cryns VL .
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression. Clin Cancer Res. 2015 Jun 15;21(12):2780-91
[PubMed ID: 25724522]
Fernando IR Ferris DP Frasconi M Malin D Strekalova E Yilmaz MD Ambrogio MW Algaradah MM Hong MP Chen X Nassar MS Botros YY Cryns VL Stoddart JF .
Esterase- and pH-responsive poly(β-amino ester)-capped mesoporous silica nanoparticles for drug delivery. Nanoscale. 2015 Apr 28;7(16):7178-83
[PubMed ID: 25820516]
Halo TL McMahon KM Angeloni NL Xu Y Wang W Chinen AB Malin D Strekalova E Cryns VL Cheng C Mirkin CA Thaxton CS .
NanoFlares for the detection, isolation, and culture of live tumor cells from human blood. Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17104-9
[PubMed ID: 25404304]
Moyer TJ Finbloom JA Chen F Toft DJ Cryns VL Stupp SI .
pH and amphiphilic structure direct supramolecular behavior in biofunctional assemblies. J Am Chem Soc. 2014 Oct 22;136(42):14746-52
[PubMed ID: 25310840]
Malin D Strekalova E Petrovic V Deal AM Al Ahmad A Adamo B Miller CR Ugolkov A Livasy C Fritchie K Hamilton E Blackwell K Geradts J Ewend M Carey L Shusta EV Anders CK Cryns VL .
αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res. 2014 Jan 1;20(1):56-67
[PubMed ID: 24132917]
Frasconi M Liu Z Lei J Wu Y Strekalova E Malin D Ambrogio MW Chen X Botros YY Cryns VL Sauvage JP Stoddart JF .
Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc. 2013 Aug 7;135(31):11603-13
[PubMed ID: 23815127]
Petrovic V Malin D Cryns VL .
αB-crystallin promotes oncogenic transformation and inhibits caspase activation in cells primed for apoptosis by Rb inactivation. Breast Cancer Res Treat. 2013 Apr;138(2):415-25
[PubMed ID: 23471649]
Goldberg MS Hook SS Wang AZ Bulte JW Patri AK Uckun FM Cryns VL Hanes J Akin D Hall JB Gharkholo N Mumper RJ .
Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond). 2013 Feb;8(2):299-308
[PubMed ID: 23394158]
Toft DJ Moyer TJ Standley SM Ruff Y Ugolkov A Stupp SI Cryns VL .
Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer. ACS Nano. 2012 Sep 25;6(9):7956-65
[PubMed ID: 22928955]
Soukasene S Toft DJ Moyer TJ Lu H Lee HK Standley SM Cryns VL Stupp SI .
Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. ACS Nano. 2011 Nov 22;5(11):9113-21
[PubMed ID: 22044255]
Su J Chen F Cryns VL Messersmith PB .
Catechol polymers for pH-responsive, targeted drug delivery to cancer cells. J Am Chem Soc. 2011 Aug 10;133(31):11850-3
[PubMed ID: 21751810]
Malin D Chen F Schiller C Koblinski J Cryns VL .
Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer. Clin Cancer Res. 2011 Aug 1;17(15):5005-15
[PubMed ID: 21653692]
Toft DJ Cryns VL .
Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2011 Feb;25(2):199-211
[PubMed ID: 20861225]
Antin JH Aplin AE Cheng SY Emmert-Buck MR Cryns VL Wang D .
American journal of cancer research: editorial board (2011). Am J Cancer Res. 2011;1(6):817-22
[PubMed ID: 22016829]
Antin JH Emmert-Buck MR Aplin AE Cheng SY Cryns VL Wang D .
Launching of American Journal of Cancer Research. Am J Cancer Res. 2011;1(1):i
[PubMed ID: 21969259]
Oshita SE Chen F Kwan T Yehiely F Cryns VL .
The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway. Breast Cancer Res Treat. 2010 Nov;124(2):307-15
[PubMed ID: 20087649]
Lee SM Ahn RW Chen F Fought AJ O'Halloran TV Cryns VL Nguyen ST .
Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano. 2010 Sep 28;4(9):4971-8
[PubMed ID: 20738118]
Ahn RW Chen F Chen H Stern ST Clogston JD Patri AK Raja MR Swindell EP Parimi V Cryns VL O'Halloran TV .
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res. 2010 Jul 15;16(14):3607-17
[PubMed ID: 20519360]
Evans JR Bosman JD Brown-Endres L Yehiely F Cryns VL .
Induction of the small heat shock protein alphaB-crystallin by genotoxic stress is mediated by p53 and p73. Breast Cancer Res Treat. 2010 Jul;122(1):159-68
[PubMed ID: 19777343]